New drug for advanced solid tumors with HRR gene change
Part of Cancer clinical trials.
This study tests a new drug (HSK46256) for people with advanced solid tumors that have a specific DNA repair gene change (HRR mutation). It is a first-in-human trial to find the right dose and check safety, so it may be an option if other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and willing to take part in the study.
- You have advanced cancer (solid tumor) that no longer responds to standard treatments, or you cannot tolerate them.
- Your tumor has a specific gene change called an HRR mutation (confirmed by a test).
- You are in generally good health (able to do light activities, expected to live at least 3 months).
- You agree to provide tumor tissue or blood samples, and use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HSK39775 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for people who have few other options.
This trial tests a new drug, HRS-4642, combined with other cancer treatments for people with advanced solid tumors. It looks at how well the combination works and if it is safe for you.
This trial tests a new drug (HS-10370) in combination with other cancer treatments for people with advanced solid tumors that have a specific genetic change (KRAS G12C). It's for patients who have tried standard options without success.
This Phase 1 trial tests HS-10386 (an experimental treatment) in people with advanced solid tumors that can’t be cured with standard options. The goal is to find a safe dose and see how the cancer responds.
This Phase 1 study tests HS-10502 in people with advanced solid tumors that have certain DNA repair problems (HRR or HRD). It may help by finding a safe dose and seeing whether the drug can shrink tumors in cancers that have specific genetic features.
This early-phase study tests XL309 (and sometimes a mix of XL309 with another treatment) in people whose advanced solid tumors have specific DNA-repair gene changes, such as BRCA1/2 or other HRR-related changes. It aims to see how well the drug works and what dose is safest for these cancers.
Hear when a new Advanced Solid Tumor (Phase 1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.